Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olopatadine PPDS for Ragweed Allergic Conjunctivitis
NCT01287338Phase 2Terminated
- Sponsor
- Mati Therapeutics
- Start
- Oct 2010
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olopatadine in seasonal allergic conjunctivitis (SAC), sponsored by Mati Therapeutics. Started Oct 2010; status: terminated.
02
Drugs
olopatadine
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on NCT01287338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287338.